MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 465877 | Name: Lenrispodun

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lenrispodun, also known as ITI-214, is a novel, potent, and selective PDE1 inhibitor.

Chemical Structure

Lenrispodun
Lenrispodun
CAS#1160521-50-5 (free base)

Theoretical Analysis

MedKoo Cat#: 465877

Name: Lenrispodun

CAS#: 1160521-50-5 (free base)

Chemical Formula: C29H26FN7O

Exact Mass: 507.2183

Molecular Weight: 507.57

Elemental Analysis: C, 68.62; H, 5.16; F, 3.74; N, 19.32; O, 3.15

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
1642303-38-5 (phosphate) 1160521-50-5 (free base)
Synonym
ITI-214; ITI 214; ITI214; Lenrispodun;
IUPAC/Chemical Name
(6aR,9aS)-2-(4-(6-fluoropyridin-2-yl)benzyl)-5-methyl-3-(phenylamino)-5,6a,7,8,9,9a-hexahydrocyclopenta[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(2H)-one
InChi Key
BBIPVJCGIASXJB-PKTZIBPZSA-N
InChi Code
InChI=1S/C29H26FN7O/c1-35-28(38)25-26(31-20-7-3-2-4-8-20)36(34-27(25)37-23-11-5-10-22(23)33-29(35)37)17-18-13-15-19(16-14-18)21-9-6-12-24(30)32-21/h2-4,6-9,12-16,22-23,31H,5,10-11,17H2,1H3/t22-,23+/m1/s1
SMILES Code
O=C1C2=C(NC3=CC=CC=C3)N(CC4=CC=C(C5=NC(F)=CC=C5)C=C4)N=C2N6[C@@]7([H])CCC[C@@]7([H])N=C6N1C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 507.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Muller GK, Song J, Jani V, Wu Y, Liu T, Jeffreys WPD, O'Rourke B, Anderson ME, Kass DA. PDE1 Inhibition Modulates Cav1.2 Channel to Stimulate Cardiomyocyte Contraction. Circ Res. 2021 Oct 15;129(9):872-886. doi: 10.1161/CIRCRESAHA.121.319828. Epub 2021 Sep 15. PMID: 34521216; PMCID: PMC8553000. 2: Yang HW, Lin CY, Lin FZ, Yu PL, Huang SM, Chen YC, Tsai CS, Yang HY. Phosphodiesterase-1 inhibitor modulates Ca2+ regulation in sirtuin 1-deficient mouse cardiomyocytes. Eur J Pharmacol. 2021 Nov 5;910:174498. doi: 10.1016/j.ejphar.2021.174498. Epub 2021 Sep 8. PMID: 34506778. 3: Gilotra NA, DeVore AD, Povsic TJ, Hays AG, Hahn VS, Agunbiade TA, DeLong A, Satlin A, Chen R, Davis R, Kass DA. Acute Hemodynamic Effects and Tolerability of Phosphodiesterase-1 Inhibition With ITI-214 in Human Systolic Heart Failure. Circ Heart Fail. 2021 Sep;14(9):e008236. doi: 10.1161/CIRCHEARTFAILURE.120.008236. Epub 2021 Aug 31. PMID: 34461742; PMCID: PMC8458252. 4: Golshiri K, Ataei Ataabadi E, Rubio-Beltran E, Dutheil S, Yao W, Snyder GL, Davis RE, van der Pluijm I, Brandt R, Van den Berg-Garrelds IM, MaassenVanDenBrink A, de Vries R, Danser AHJ, Roks AJM. Selective Phosphodiesterase 1 Inhibition Ameliorates Vascular Function, Reduces Inflammatory Response, and Lowers Blood Pressure in Aging Animals. J Pharmacol Exp Ther. 2021 Aug;378(2):173-183. doi: 10.1124/jpet.121.000628. Epub 2021 Jun 7. PMID: 34099502. 5: Yugo D, Chen YC, Lin YK, Liu CM, Huang JH, Chen SA, Chen YJ. Effects of phosphodiesterase-1 inhibitor on pulmonary vein electrophysiology and arrhythmogenesis. Eur J Clin Invest. 2021 Sep;51(9):e13585. doi: 10.1111/eci.13585. Epub 2021 May 18. PMID: 34002387. 6: O'Brien JJ, O'Callaghan JP, Miller DB, Chalgeri S, Wennogle LP, Davis RE, Snyder GL, Hendrick JP. Inhibition of calcium-calmodulin-dependent phosphodiesterase (PDE1) suppresses inflammatory responses. Mol Cell Neurosci. 2020 Jan;102:103449. doi: 10.1016/j.mcn.2019.103449. Epub 2019 Nov 23. PMID: 31770590; PMCID: PMC7783477. 7: Hashimoto T, Kim GE, Tunin RS, Adesiyun T, Hsu S, Nakagawa R, Zhu G, O'Brien JJ, Hendrick JP, Davis RE, Yao W, Beard D, Hoxie HR, Wennogle LP, Lee DI, Kass DA. Acute Enhancement of Cardiac Function by Phosphodiesterase Type 1 Inhibition. Circulation. 2018 Oct 30;138(18):1974-1987. doi: 10.1161/CIRCULATIONAHA.117.030490. PMID: 30030415; PMCID: PMC6205901. 8: Pekcec A, Schülert N, Stierstorfer B, Deiana S, Dorner-Ciossek C, Rosenbrock H. Targeting the dopamine D1 receptor or its downstream signalling by inhibiting phosphodiesterase-1 improves cognitive performance. Br J Pharmacol. 2018 Jul;175(14):3021-3033. doi: 10.1111/bph.14350. Epub 2018 Jun 3. PMID: 29726015; PMCID: PMC6016630. 9: Wennogle LP, Hoxie H, Peng Y, Hendrick JP. Phosphodiesterase 1: A Unique Drug Target for Degenerative Diseases and Cognitive Dysfunction. Adv Neurobiol. 2017;17:349-384. doi: 10.1007/978-3-319-58811-7_13. PMID: 28956339. 10: Snyder GL, Prickaerts J, Wadenberg ML, Zhang L, Zheng H, Yao W, Akkerman S, Zhu H, Hendrick JP, Vanover KE, Davis R, Li P, Mates S, Wennogle LP. Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats. Psychopharmacology (Berl). 2016 Sep;233(17):3113-24. doi: 10.1007/s00213-016-4346-2. Epub 2016 Jun 24. PMID: 27342643; PMCID: PMC4980415. 11: Li P, Zheng H, Zhao J, Zhang L, Yao W, Zhu H, Beard JD, Ida K, Lane W, Snell G, Sogabe S, Heyser CJ, Snyder GL, Hendrick JP, Vanover KE, Davis RE, Wennogle LP. Discovery of Potent and Selective Inhibitors of Phosphodiesterase 1 for the Treatment of Cognitive Impairment Associated with Neurodegenerative and Neuropsychiatric Diseases. J Med Chem. 2016 Feb 11;59(3):1149-64. doi: 10.1021/acs.jmedchem.5b01751. Epub 2016 Feb 2. PMID: 26789933.